Lobe Sciences Ltd.: Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("
Lobe" or the "
Company") announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. As announced on December 3, 2020, the Company engaged VisionWorks Engineering of San Diego, CA to complete this first phase of development. Lobe's nasal mist device delivers "micro doses" of pharmaceutical agents such as a psilocybin and N-acetylcysteine ("
NAC") at preselected dosages.
Philip Young, CEO of Lobe states "Advancing through the initial development and testing of our innovative nasal mist device will position Lobe as the leader in the delivery of effective therapeutics to treat patients suffering from mild traumatic brain injury, post-traumatic stress disorder, and other mental health conditions. We intend to further the development of this device leading to commercialization. Completing the development of this device will enable the patients to easily treat themselves where they live and work."